人脐带血间充质干细胞治疗脑梗死的临床疗效研究

目的观察人脐带血间充质干细胞治疗脑梗死的临床疗效。方法选取我院2010年9月—2013年2月收治的脑梗死患者100例,将其随机分为治疗组和对照组,各50例。对照组给予常规药物治疗,同时予以康复训练;治疗组在对照组治疗基础上给予人脐带血间充质干细胞治疗。按照美国国立卫生院神经功能缺损评分(NIHSS)和简式Fugl-Meyer运功功能(FMA)评分评价治疗前,治疗后1、2、3个月时两组患者的神经功能缺损情况。结果治疗前、治疗后1个月、治疗后2个月,两组患者NHISS评分和FMA评分比较,差异均无统计学意义(P0.05);治疗后3个月,治疗组NHISS评分低于对照组,FMA评分高于对照组(P0.05)。治疗组有1例患者出现低热反应,余未发现其他不良反应。结论人脐带血间充质干细胞治疗脑梗死疗效明显,可以明显改善患者的临床症状,且不良反应少。

Effect of Human Umbilical Cord Blood - derived Mesenchymal Stem Cells in the Treatment of Cerebral Infarction

Objective To observe the effect of human umbilical cord blood - derived mesenchymal stem cells in the treatment of cerebral infarction. Methods 100 patients with cerebral infarction were chosen in our hospital from Semptember 2010 to February 2013, they were randomly divided into treatment group and control group, 50 eases in each. The control group were treated by conventional drug and rehabilitation training; based on the control group, the treatment group were treated by hu- man unrbilical cord blood - derived mesenehymal stem cells. The neurological deficit situation of two groups were evaluated ac- cording to the National Institute of Health Stroke Scale （NIHSS） score and simplified Fugl - Meyer pump power function （FMA） score before treatment, 1, 2, 3 months after treatment. Results There was no statistically significant difference in the NHISS score and FMA score between two groups before treatment, I, 2 months after treatment （ P 〉 0.05 ） ; 3 months after treatment, the NHISS score of treatment group was lower than that of control group, the FMA score was higher than that of control group （ P 〈 O. 05 ）. In treatment group, 1 case had a fever, and no other adverse reaction recorded. Conclusion Human um- bilical cord blood - derived mesenehymal stem ceils is effective in the treatment of cerebral infarction, which can significantly im- prove the clinical symptoms, and is with fewer adverse reactions.